18:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Osaka University grants Otsuka rights to MMG49

Osaka University (Osaka, Japan) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive, worldwide rights to patents associated with MMG49, a CAR T cell therapy that targets the active conformer of integrin β(7). The university will...
16:13 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Mouse studies suggest inhibiting the integrin CD29 could help treat vascular leakage caused by endotoxemia associated with sepsis. In a lipopolysaccharide (LPS)-induced mouse model of endotoxemia, an anti-CD29 mAb decreased vascular leakage and...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis...
17:07 , Nov 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting integrin β 7 could help treat MM. In bone marrow samples from patients, co-culture with CAR...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in...
19:30 , Sep 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Integrin β3 -targeted nanoparticles could deliver chemotherapies to treat bone metastases of breast cancer. The nanoparticles consist of phospholipid/polysorbate 80 micelles loaded with drug and coated with an integrin αvβ3 ( CD51/CD61 )-binding...
21:45 , May 12, 2017 |  BioCentury  |  Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
18:50 , May 1, 2017 |  BC Extra  |  Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution , an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million...